Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Bio Reports Novel Bi-Specific is Effective in AMD Trial

publication date: Nov 16, 2020

Suzhou Innovent reported its bi-specific fusion protein was effective in patients with neovascular age-related macular degeneration (nAMD). The Phase I trial showed the 31 participants were able to read six additional letters in an eye exam following a single treatment. Innovent's IBI302 is a first-in-class recombinant human anti-VEGF and anti-complement bi-specific molecule. The complement system is part of the innate immune response. Although VEGF drugs have revolutionized treatment for AMD, some patients develop resistance to them over time. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.